SG Americas Securities LLC Invests $504,000 in Celldex Therapeutics, Inc. $CLDX

SG Americas Securities LLC purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 19,468 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the second quarter valued at $125,000. Tower Research Capital LLC TRC boosted its stake in Celldex Therapeutics by 289.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 5,387 shares during the last quarter. Finally, Overbrook Management Corp acquired a new position in Celldex Therapeutics during the 3rd quarter worth $228,000.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $25.92 on Friday. The firm has a market capitalization of $1.72 billion, a P/E ratio of -7.67 and a beta of 1.19. The business has a 50 day simple moving average of $26.67 and a 200 day simple moving average of $25.04. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $30.50.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. Research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CLDX. Barclays upped their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday. Finally, Mizuho began coverage on Celldex Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.10.

Insiders Place Their Bets

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the completion of the transaction, the insider directly owned 20,833 shares of the company’s stock, valued at $499,992. The trade was a 70.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.40% of the stock is currently owned by corporate insiders.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.